Please assess the completion status of the following clinical trial:

Trial Title: Ruxolitinib In GvHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Acute skin, intestinal (histologically confirmed) or liver GvHD \> grade 1 according to standard criteria~2. Age ≥18 years~3. Failure of previous treatment, defined as presence of at least one of the following criteria:~   1. Treatment with prednisone/prednisolone/methylprednisolone in a dose of at least 2 mg/kg and lack of response after at least 7 days treatment~  2. Treatment with prednisone/prednisolone/methylprednisolone in a dose of at least 2 mg/kg and progression after at least 3 days of treatment~  3. Failure to taper the prednisone/prednisolone dose to \<0.6 mg/kg/day or methylprednisolone dose to \<0.5 mg/kg/day~4. Written informed consent~5. Ability to understand the nature of the study and the study related procedures and to comply with them~Exclusion Criteria:~1. Uncontrolled underlying disease~2. Active bleeding~3. Absence of clinical signs of acute GvHD~4. Diagnostic or distinctive clinical signs of chronic GvHD~5. Uncontrolled bacterial, viral or fungal infection~6. Absolute neutrophil count \<0.5x103/µl~7. Evidence of transplant-associated micrioangiopathy (TAM) (According to Jodele et al., 2015, diagnostic criteria for TAM)~8. Any previous JAK2 inhibitor treatment prior to study enrolment, except Ruxolitinib given prior to the allogeneic stem cell transplantation~9. Known Hypersensitivity to Ruxolitinib or any of the excipients~10. Known positivity for HIV, Hepatitis B or Hepatitis C at the time of screening.~11. Female patients who are pregnant or breast feeding~12. Concomitant use of any other investigational drug within the last thirty days before the start of this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental intervention (Type: EXPERIMENTAL): Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines.
- Standard treatment (Type: ACTIVE_COMPARATOR): Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of March 2018). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.

Based on this trial design, predict the completion outcome and termination type (if applicable).